Annals of Nuclear Medicine最新文献

{"title":"Animal PET scanner with a large field of view is suitable for high-throughput scanning of rodents","authors":"Yuki Tomonari,&nbsp;Yuya Onishi,&nbsp;Fumio Hashimoto,&nbsp;Kibo Ote,&nbsp;Takashi Okamoto,&nbsp;Hiroyuki Ohba","doi":"10.1007/s12149-024-01937-1","DOIUrl":"10.1007/s12149-024-01937-1","url":null,"abstract":"<div><h3>Objective</h3><p>In preclinical studies, high-throughput positron emission tomography (PET) imaging, known as simultaneous multiple animal scanning, can reduce the time spent on animal experiments, the cost of PET tracers, and the risk of synthesis of PET tracers. It is well known that the image quality acquired by high-throughput imaging depends on the PET system. Herein, we investigated the influence of large field of view (FOV) PET scanner on high-throughput imaging.</p><h3>Methods</h3><p>We investigated the influence of scanning four objects using a small animal PET scanner with a large FOV. We compared the image quality acquired by four objects scanned with the one acquired by one object scanned using phantoms and animals. We assessed the image quality with uniformity, recovery coefficient (RC), and spillover ratio (SOR), which are indicators of image noise, spatial resolution, and quantitative precision, respectively. For the phantom study, we used the NEMA NU 4-2008 image quality phantom and evaluated uniformity, RC, and SOR, and for the animal study, we used Wistar rats and evaluated the spillover in the heart and kidney.</p><h3>Results</h3><p>In the phantom study, four phantoms had little effect on imaging quality, especially SOR compared with that for one phantom. In the animal study as well, four rats had little effect on spillover from the heart muscle and kidney cortex compared with that for one rat.</p><h3>Conclusions</h3><p>This study demonstrated that an animal PET scanner with a large FOV was suitable for high-throughput imaging. Thus, the large FOV PET scanner can support drug discovery and bridging research through rapid pharmacological and pathological evaluation.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 7","pages":"544 - 552"},"PeriodicalIF":2.5,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140875658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of combining clinical factors, 18F-FDG PET-based intensity, volumetric features, and deep learning predictor in patients with EGFR-mutated lung adenocarcinoma undergoing targeted therapies: a cross-scanner and temporal validation study","authors":"Kun-Han Lue,&nbsp;Yu-Hung Chen,&nbsp;Sung-Chao Chu,&nbsp;Chih-Bin Lin,&nbsp;Tso-Fu Wang,&nbsp;Shu-Hsin Liu","doi":"10.1007/s12149-024-01936-2","DOIUrl":"10.1007/s12149-024-01936-2","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the prognostic value of ¹⁸F-FDG PET-based intensity, volumetric features, and deep learning (DL) across different generations of PET scanners in patients with epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma receiving tyrosine kinase inhibitor (TKI) treatment.</p><h3>Methods</h3><p>We retrospectively analyzed the pre-treatment ¹⁸F-FDG PET of 217 patients with advanced-stage lung adenocarcinoma and actionable EGFR mutations who received TKI as first-line treatment. Patients were separated into analog (<i>n</i> = 166) and digital (<i>n</i> = 51) PET cohorts. ¹⁸F-FDG PET-derived intensity, volumetric features, ResNet-50 DL of the primary tumor, and clinical variables were used to predict progression-free survival (PFS). Independent prognosticators were used to develop prediction model. Model was developed and validated in the analog and digital PET cohorts, respectively.</p><h3>Results</h3><p>In the analog PET cohort, female sex, stage IVB status, exon 19 deletion, SUV_max, metabolic tumor volume, and positive DL prediction independently predicted PFS. The model devised from these six prognosticators significantly predicted PFS in the analog (HR = 1.319, <i>p</i> &lt; 0.001) and digital PET cohorts (HR = 1.284, <i>p</i> = 0.001). Our model provided incremental prognostic value to staging status (c-indices = 0.738 vs. 0.558 and 0.662 vs. 0.598 in the analog and digital PET cohorts, respectively). Our model also demonstrated a significant prognostic value for overall survival (HR = 1.198, <i>p</i> &lt; 0.001, c-index = 0.708 and HR = 1.256, <i>p</i> = 0.021, c-index = 0.664 in the analog and digital PET cohorts, respectively).</p><h3>Conclusions</h3><p>Combining ¹⁸F-FDG PET-based intensity, volumetric features, and DL with clinical variables may improve the survival stratification in patients with advanced EGFR-mutated lung adenocarcinoma receiving TKI treatment. Implementing the prediction model across different generations of PET scanners may be feasible and facilitate tailored therapeutic strategies for these patients.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 8","pages":"647 - 658"},"PeriodicalIF":2.5,"publicationDate":"2024-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140858690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of 68 Ga-FAPI PET/CT in patients with bone metastases in various cancers","authors":"Hacı Arak,&nbsp;Umut Elboga,&nbsp;Yusuf Burak Cayirli,&nbsp;Aydın Aytekin","doi":"10.1007/s12149-024-01935-3","DOIUrl":"10.1007/s12149-024-01935-3","url":null,"abstract":"<div><h3>Objective</h3><p>This study aimed to compare ¹⁸FDGPET/CT in patients who develop bone metastases due to various cancers and to investigate the prognostic significance of the ⁶⁸FAPI-PET/CT SUVmax value for survival.</p><h3>Methods</h3><p>Patients with bone metastases who underwent both ⁶⁸ Ga-FAPI PET/CT and ¹⁸FDGPET/CT within a 1 week period were included in this retrospective study. The effect of the SUVmax value of bone lesions on overall survival was analyzed.</p><h3>Results</h3><p>A total of 75 eligible patients with 139 bone lesions were included in this study. The median age of the patients was 55 (30–83) and 48(64%) patients were newly diagnosed. The primary lesion median ⁶⁸ Ga-FAPI PET/CT SUVmax value was higher than the median ¹⁸FDGPET/CT SUVmax (10.75 versus 6.7). Bone lesions ⁶⁸ Ga-FAPI PET/CT SUVmax median (IQR) were 7.8 (4.6–13.2), and ¹⁸FDGPET/CT SUVmax of bone lesions were 5.9 (3.8–8.2). More bone lesions were detected on ⁶⁸ Ga-FAPI PET/CT than on ¹⁸FDGPET/CT(median IQR 4 [1–9] versus 2 [1–6] (<i>p</i> = 0.014). The extra lesions observed on ⁶⁸ Ga-FAPI PET/CT were mostly sclerotic bone lesions (<i>p</i> = 0.001).⁶⁸ Ga-FAPI PET/CT SUVmax was significantly higher in vertebra and thorax lesions (<i>p</i> = 0.011 and <i>p</i> = 0.018, respectively). While the bone lesion ⁶⁸ Ga-FAPI PET/CT SUVmax affected the OS, the ¹⁸FDGPET/CT SUVmax value did not affect the OS (<i>p</i> &lt; 0.001 and <i>p</i> = 0.079, respectively). In ROC analysis, a cut-off-off value of ⁶⁸ Ga-FAPI PET/CT SUVmax &gt; 7.7 was found for OS (AUC: 0.619). The median OS in the group above the cut-off value was worse than that in the group below the cut-off value (32 versus 45) months (<i>p</i> = 0.002). In the multivariate analysis for OS, the ⁶⁸ Ga-FAPI PET/CT SUVmax of bone lesions was an important parameter, as well as cancer subtype, ALP level, and disease occurrence.</p><h3>Conclusions</h3><p>⁶⁸ Ga-FAPI PET/CT detected more bone lesions and higher SUVmax values than ¹⁸FDGPET/CT in various cancers. The prognostic value of the SUVmax value of ⁶⁸ Ga-FAPI PET/CT bone lesions was observed regardless of disease subtype.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 8","pages":"630 - 638"},"PeriodicalIF":2.5,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140837504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fundamental evaluation regarding the relationship between albumin-binding and tumor accumulation of PSMA-targeting radioligands","authors":"Nobuki Kazuta,&nbsp;Shohei Tsuchihashi,&nbsp;Hiroyuki Watanabe,&nbsp;Masahiro Ono","doi":"10.1007/s12149-024-01930-8","DOIUrl":"10.1007/s12149-024-01930-8","url":null,"abstract":"<div><h3>Objective</h3><p>The marked success of prostate-specific membrane antigen (PSMA)-targeting radioligands with albumin binder (ALB) is attributed to the improvement of blood retention and tumor accumulation. [¹¹¹In]In-PNT-DA1, our PSMA-targeting radioligand with ALB, also achieved improved tumor accumulation due to its prolonged blood retention. Although the advantage of ALBs is related to their reversible binding to albumin, the relationship between albumin-binding and tumor accumulation of PSMA-targeting radioligands remains unclear because of the lack of information about radioligands with stronger albumin-binding than ALBs. In this study, we designed and synthesized [¹¹¹In]In-PNT-DM-HSA, a new radioligand that consists of a PSMA-targeting radioligand covalently bound to albumin. The pharmacokinetics of [¹¹¹In]In-PNT-DM-HSA was compared with those of [¹¹¹In]In-PNT-DA1 and [¹¹¹In]In-PSMA-617, a non-ALB-conjugated radioligand, to evaluate the relationship between albumin-binding and tumor accumulation.</p><h3>Method</h3><p>The [¹¹¹In]In-PNT-DM-HSA was prepared by incubation of [¹¹¹In]In-PNT-DM, a PSMA-targeting radioligand including a maleimide group, and human serum albumin (HSA). The ability of [¹¹¹In]In-PNT-DM-HSA was evaluated by in vitro assays. A biodistribution study using LNCaP tumor-bearing mice was conducted to compare the pharmacokinetics of [¹¹¹In]In-PNT-DM-HSA, [¹¹¹In]In-PNT-DA1, and [¹¹¹In]In-PSMA-617.</p><h3>Results</h3><p>The [¹¹¹In]In-PNT-DM-HSA was obtained at a favorable radiochemical yield and high radiochemical purity. In vitro assays revealed that [¹¹¹In]In-PNT-DM-HSA had fundamental characteristics as a PSMA-targeting radioligand interacting with albumin covalently. In a biodistribution study, [¹¹¹In]In-PNT-DM-HSA and [¹¹¹In]In-PNT-DA1 showed higher blood retention than [¹¹¹In]In-PSMA-617. On the other hand, the tumor accumulation of [¹¹¹In]In-PNT-DA1 was much higher than [¹¹¹In]In-PNT-DM-HSA and [¹¹¹In]In-PSMA-617.</p><h3>Conclusions</h3><p>These results indicate that the moderate reversible binding of ALB with albumin, not covalent binding, may play a critical role in enhancing the tumor accumulation of PSMA-targeting radioligands.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 7","pages":"574 - 583"},"PeriodicalIF":2.5,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140798043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of regional and total skeletal metabolism using 18F-NaF PET/CT in patients with chronic kidney disease","authors":"Sharjeel Usmani,&nbsp;Najeeb Ahmed,&nbsp;Gopinath Gnanasegaran,&nbsp;Fahad Marafi,&nbsp;Ahmed Bani-Mustafa,&nbsp;Tim Van den Wyngaert","doi":"10.1007/s12149-024-01929-1","DOIUrl":"10.1007/s12149-024-01929-1","url":null,"abstract":"<div><h3>Objective</h3><p>The study aims to assess regional and total bone metabolic activity in patients with chronic kidney disease using Na[¹⁸F]F PET and correlation between semi-quantitative indices and blood parameters.</p><h3>Methods</h3><p>Seventy-two subjects (mean age 61.8 ± 13.8 years) were included. Of these 24/72 patients had end-stage renal disease (ESRD) (GFR &lt; 15 mL/min/1.73 m²), 38/72 had chronic kidney disease (CKD) (GFR between 60 and 15 mL/min/1.73 m²), and 10/72 were controls with normal renal function. All subjects underwent Na[¹⁸F]F PET-CT with a dose activity of 0.06 mCi/Kg. Regional and total skeletal metabolism were assessed with mean SUVs in a skeletal volume of interest (VOI), bone to soft tissue index (B/S), global SUV mean (GSUV mean) of the whole bone, and uptake in the femoral neck.</p><h3>Results</h3><p>Statistically significant differences were observed in a number of ¹⁸F-NaF metrics like femoral neck metabolism in CKD and ERSD groups in comparison to control in right (<i>P</i> = 0.003) and left femur (<i>P</i> = 0.006), bone to soft tissue index in the femur (<i>P</i> = 0.016) and GSUV₅ (<i>P</i> = 0.006). There is also a significant difference in SUV mean in lumbar vertebrae (L1–L4) among CKD, ESRD, and controls. There was a moderate correlation between ¹⁸F-NaF PET scan uptake and blood parameters such as ALP and PTH. Na[¹⁸F]F uptake parameters were significantly different in low versus high bone turnover state.</p><h3>Conclusions</h3><p>The assessment of total skeleton and regional metabolism and bone turnover in CKD patients is feasible with Na[¹⁸F]F PET. Na[¹⁸F]F can help to detect early changes in bone metabolism and assess the progression of bone disease in this complex condition. Quantification with Na[¹⁸F]F PET might provide better assessment of the bone turnover. The difference in Na[¹⁸F]F uptake in CKD compared to controls is likely related to a change in bone turnover which, however, requires further validation.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 7","pages":"563 - 573"},"PeriodicalIF":2.5,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140797968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of multiple-dose versus single-dose MIBG therapy in patients with refractory pheochromocytoma and paraganglioma: a single-center retrospective analysis","authors":"Naoto Wakabayashi,&nbsp;Shiro Watanabe,&nbsp;Takashige Abe,&nbsp;Junki Takenaka,&nbsp;Kenji Hirata,&nbsp;Rina Kimura,&nbsp;Keita Sakamoto,&nbsp;Nobuo Shinohara,&nbsp;Kohsuke Kudo","doi":"10.1007/s12149-024-01928-2","DOIUrl":"10.1007/s12149-024-01928-2","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the incidence of adverse events (AEs) following single and multiple administrations of I-131 metaiodobenzylguanidine (MIBG) therapy for inoperable pheochromocytomas and paragangliomas (PPGLs).</p><h3>Methods</h3><p>A single-center retrospective study was conducted on patients with inoperable PPGLs who underwent I-131 MIBG therapy between January 2000 and December 2020. A total of 28 patients with available electronic medical records were included. The treatment consisted of a single intravenous administration of 150 mCi (5.55 GBq) of I-131 MIBG. We evaluated the first MIBG treatment and repeated MIBG treatments performed within 200 days of the previous treatment. AEs for each treatment were evaluated using CTCAE version 4.0, and the statistical analysis was conducted at a significance level of <i>p</i> &lt; 0.05. Objective response based on RECIST 1.1 criteria and biochemical response based on urinary catecholamines were assessed.</p><h3>Results</h3><p>The study included a total of 63 administrations, consisting of 28 single administrations (SAs), including the first administration for all 28 cases, and 35 multiple administrations (MAs), which included the second or later administrations. Hematological AEs were evaluable for 23 SAs and 29 MAs. Grade 3 or higher leukopenia occurred in 9.8% of all administrations, and Grade 3 or higher lymphopenia in 23.5%; both were manageable through observation. There were no significant differences in clinical AE Grades 1–2 (<i>p</i> = 0.32), hematological AE Grades 1–2 (<i>p</i> = 0.22), or hematological AE Grades 3–4 (<i>p</i> = 0.12) between MAs and SAs. Statistical analysis for each type of AE revealed significant increases in leukopenia (<i>p</i> &lt; 0.01) and lymphopenia (<i>p</i> = 0.04). No significant difference in anemia, thrombocytopenia, or neutropenia was observed between MAs and SAs. There was no significant increase in the incidence rate of Grade 3 or higher hematological AEs for any of the parameters. The objective response rate was 0% for SAs and 36% for MAs. Biochemical response rates were 18% for SAs and 67% for MAs.</p><h3>Conclusion</h3><p>In I-131 MIBG therapy for PPGLs, multiple administrations significantly increased only Grade 1 or 2 lymphopenia and leukopenia compared to single administration.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 7","pages":"553 - 562"},"PeriodicalIF":2.5,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140664251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increase of prostate-specific antigen doubling time predicts survival in metastatic castration-resistant prostate cancer patients undergoing radium therapy","authors":"Hsi-Huei Lu,&nbsp;Nan-Tsing Chiu,&nbsp;Mu-Hung Tsai","doi":"10.1007/s12149-024-01924-6","DOIUrl":"10.1007/s12149-024-01924-6","url":null,"abstract":"<div><h3>Objective</h3><p>Radium-223 (Ra-223) is an important treatment modality for bone-dominant metastatic castration-resistant prostate cancer (mCRPC). However, there is currently a lack of effective markers to monitor treatment response during treatment. We aim to investigate the response in prostate-specific antigen doubling time (PSADT) as a potential marker for assessing Ra-223 treatment in mCRPC patients.</p><h3>Methods</h3><p>We retrospectively collected data from mCRPC patients who underwent radium treatment at our institution between August 2020 and June 2023. Prostate-specific antigen (PSA) measurements prior to treatment and during treatment were collected. Baseline PSADT was calculated from PSA measurements prior to Ra-223 treatment; interim PSADT was calculated from PSA measurements before Ra-223 treatment and prior to the fourth course injection. Overall survival was calculated from the start of treatment to the date of death. Univariable and multivariable analysis using the Cox proportional hazards model were performed to examine the association of factors with overall survival.</p><h3>Results</h3><p>We included 35 patients from our institution, with a median overall survival of 13.3 months. Eighteen (51.4%) completed all six courses of treatment. PSA dynamic response (interim PSADT &gt; baseline PSADT or decreased PSA) was observed in 20 patients. Overall survival was associated with a PSA dynamic response (HR = 0.318, 95% CI 0.133–0.762, <i>p</i> = 0.010) when compared to patients without response.</p><h3>Conclusions</h3><p>Dynamic changes in PSADT were associated with survival in mCRPC patients receiving radium therapy. Comparing interim and baseline PSADT could serve as a valuable marker for determining treatment benefits.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 7","pages":"508 - 515"},"PeriodicalIF":2.5,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140677589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of dose–volume histograms for metabolic response prediction in hepatocellular carcinoma patients undergoing transarterial radioembolization with Y-90 resin microspheres","authors":"Nazim Coskun,&nbsp;Mehmet Oguz Kartal,&nbsp;Aysenur Sinem Kartal,&nbsp;Velihan Cayhan,&nbsp;Mustafa Ozdemir,&nbsp;Murat Canyigit,&nbsp;Elif Ozdemir","doi":"10.1007/s12149-024-01926-4","DOIUrl":"10.1007/s12149-024-01926-4","url":null,"abstract":"<div><h3>Introduction</h3><p>Voxel-based dosimetry offers improved outcomes in the treatment of hepatocellular carcinoma (HCC) with transarterial radioembolization (TARE) using glass microspheres. However, the adaptation of voxel-based dosimetry to resin-based microspheres has been poorly studied, and the prognostic relevance of heterogeneous dose distribution remains unclear. This study aims to explore the use of dose–volume histograms for resin microspheres and to determine thresholds for objective metabolic response in HCC patients treated with resin-based TARE.</p><h3>Methods</h3><p>We retrospectively reviewed HCC patients who underwent TARE with Y-90-loaded resin microspheres in our institution between January 2021 and December 2022. Voxel-based dosimetry was performed on post-treatment Y-90 PET/CT images to extract parameters including mean dose absorbed by the tumor (mTD), the percentage of the targeted tumor volume (pTV), and the minimum doses absorbed by consecutive percentages within the tumor volume (D10, D25, D50, D75, D90). Assessment of metabolic response was done according to PERCIST criteria with F-18 FDG PET/CT imaging at 8–12 weeks after the treatment.</p><h3>Results</h3><p>This study included 35 lesions targeted with 22 TARE sessions in 19 patients (15 males, 4 females, mean age 60 ± 13 years). Objective metabolic response was achieved in 43% of the lesions (<i>n</i> = 15). Responsive lesions had significantly higher mTD, pTV, and D25-D90 values (all <i>p</i> &lt; 0.05). Optimal cut-off values for mTD, pTV, and D50 were 94.6 Gy (sensitivity 73%, specificity 70%, AUC 0.72), 94% (sensitivity 73%, specificity 55%, AUC 0.64), and 91 Gy (sensitivity 80%, specificity 80%, AUC 0.80), respectively.</p><h3>Conclusion</h3><p>Parameters derived from dose–volume histograms could offer valuable insights for predicting objective metabolic response in HCC patients treated with resin-based TARE. If verified with larger prospective cohorts, these parameters could enhance the precision of dose distribution and potentially optimize treatment outcomes.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 7","pages":"525 - 533"},"PeriodicalIF":2.5,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140675390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"No prognostic impact of staging bone scan in patients with stage IA non-small cell lung cancer","authors":"Xia Zheng,&nbsp;Chunxia Li,&nbsp;Jing Ai,&nbsp;Guili Dong,&nbsp;Man Long,&nbsp;Mingyi Li,&nbsp;Shilin Qiu,&nbsp;Yanni Huang,&nbsp;Guangjun Yang,&nbsp;Tao Zhang,&nbsp;Zhenhui Li","doi":"10.1007/s12149-024-01927-3","DOIUrl":"10.1007/s12149-024-01927-3","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the survival benefit of preoperative bone scan in asymptomatic patients with early-stage non-small cell lung cancer (NSCLC).</p><h3>Methods</h3><p>This retrospective study included patients with radical resection for stage T1N0M0 NSCLC between March 2013 and December 2018. During postoperative follow-up, we monitored patient survival and the development of bone metastasis. We compared overall survival, bone metastasis-free survival, and recurrence-free survival in patients with or without preoperative bone scan. Propensity score matching and inverse probability of treatment weighting were used to minimize election bias.</p><h3>Results</h3><p>A total of 868 patients (58.19 ± 9.69 years; 415 men) were included in the study. Of 87.7% (761 of 868) underwent preoperative bone scan. In the multivariable analyses, bone scan did not improve overall survival (hazard ratio [HR] 1.49; 95% confidence intervals [CI] 0.91–2.42; <i>p</i> = 0.113), bone metastasis-free survival (HR 1.18; 95% CI 0.73–1.90; <i>p</i> = 0.551), and recurrence-free survival (HR 0.89; 95% CI 0.58–1.39; <i>p</i> = 0.618). Similar results were obtained after propensity score matching (overall survival [HR 1.28; 95% CI 0.74–2.23; <i>p</i> = 0.379], bone metastasis-free survival [HR 1.00; 95% CI 0.58–1.72; <i>p</i> = 0.997], and recurrence-free survival [HR 0.76; 95% CI 0.46–1.24; <i>p</i> = 0.270]) and inverse probability of treatment weighting.</p><h3>Conclusion</h3><p>There were no significant differences in overall survival, bone metastasis-free survival, and recurrence-free survival between asymptomatic patients with clinical stage IA NSCLC with or without preoperative bone scan.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 7","pages":"534 - 543"},"PeriodicalIF":2.5,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140574644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of a deep-learning model using 18F-FDG PET/CT for evaluating recurrence after radiation therapy in patients with lung cancer","authors":"Changhwan Sung,&nbsp;Jungsu S. Oh,&nbsp;Byung Soo Park,&nbsp;Su Ssan Kim,&nbsp;Si Yeol Song,&nbsp;Jong Jin Lee","doi":"10.1007/s12149-024-01925-5","DOIUrl":"10.1007/s12149-024-01925-5","url":null,"abstract":"<div><h3>Objective</h3><p>We developed a deep learning model for distinguishing radiation therapy (RT)-related changes and tumour recurrence in patients with lung cancer who underwent RT, and evaluated its performance.</p><h3>Methods</h3><p>We retrospectively recruited 308 patients with lung cancer with RT-related changes observed on ¹⁸F-fluorodeoxyglucose positron emission tomography–computed tomography (¹⁸F-FDG PET/CT) performed after RT. Patients were labelled as positive or negative for tumour recurrence through histologic diagnosis or clinical follow-up after ¹⁸F-FDG PET/CT. A two-dimensional (2D) slice-based convolutional neural network (CNN) model was created with a total of 3329 slices as input, and performance was evaluated with five independent test sets.</p><h3>Results</h3><p>For the five independent test sets, the area under the curve (AUC) of the receiver operating characteristic curve, sensitivity, and specificity were in the range of 0.98–0.99, 95–98%, and 87–95%, respectively. The region determined by the model was confirmed as an actual recurred tumour through the explainable artificial intelligence (AI) using gradient-weighted class activation mapping (Grad-CAM).</p><h3>Conclusion</h3><p>The 2D slice-based CNN model using ¹⁸F-FDG PET imaging was able to distinguish well between RT-related changes and tumour recurrence in patients with lung cancer.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 7","pages":"516 - 524"},"PeriodicalIF":2.5,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140574535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}